Huntington's Disease (HD)

IXICO excels in delivering HD imaging using advanced imaging biomarkers that quantify key HD measurements, such as caudate nucleus and putamen atrophy, white matter integrity changes, and striatal susceptibility changes. Used in combination with the IXI™ Platform, this enhances our accuracy and efficacy for measuring disease-specific changes in brain region volumetrics.

With a proven track record in HD clinical trials and collaborations with key scientific institutions, such as University College London (UCL) and the CHDI Foundation, IXICO’s combination of disease-specific approaches, tools and technologies, together with deep scientific expertise, has enabled IXICO to build a reputation as the trusted partner for HD clinical trials.

Quantitative Imaging Endpoints

Diffusion MRI (Tensor Imaging, Neurite Orientation Dispersion and Density Imaging, Free Water Imaging, Structural Connectivity)

Magnetic Resonance Spectroscopy (MRS) for brain metabolic levels, Quantitative Susceptibility Mapping (QSM) to measure regional susceptibility

Functional Connectivity and Metabolism.

Neuroimaging Biomarker

Regional brain atrophy (Caudate Nucleus, Putamen, Whole Brain, Lateral Ventricles).

HD Content Portal

Our HD Factsheet

Download

Poster

Comparison of two natural history studies as part of the HD-IH consortium
Presented at HDTC 2025

View Here

Research Article

Neuroimaging to Facilitate Clinical Trials in Huntington’s Disease: Current Opinion from the EHDN Imaging Working Group - IOS Press

View Here

Poster

Volumetric change across the different Stages of the Huntington’s disease Integrated Staging System (HD-ISS) defined at baseline
Presented at EHDN 2024

View Here

Poster

Association between regional volume change and clinical change in Huntington’s disease HD-ISS Stage 2 and Stage 3 participants
Presented at HDTC 2023

View Here

Recent HD Scientific Publications

Comparison of two natural history studies as part of the HD-IH consortium: a use case for historical external control group matching in clinical trials

Date: March 11th 2025
Presentation type: Presentation at the EHDN conference
Synopsis: This study demonstrates how historical data from TRACK-HD and PREDICT-HD can be merged to form a matched external comparator group for Huntington’s disease using imaging and clinical endpoints.
Therapeutic Indication: Huntington's Disease (HD)

>View Study

Volumetric change across the different Stages of the Huntington’s disease Integrated Staging System (HD-ISS) defined at baseline

Date: September 2nd 2024
Presentation type: Presentation at the HDTC conference
Synopsis: Data from TRACK-HD/ON and PREDICT-HD,processed within the HD Imaging Harmonization consortium, were analyzed using deep-learning and gBSI methods.
Therapeutic Indication: Huntington's Disease (HD)

>View Study

Association between regional volume change and clinical change in Huntington’s disease HD-ISS Stage 2 and Stage 3 participants

Date: March 12th 2024
Synopsis: This study demonstrates how historical data from TRACK-HD and PREDICT-HD can be merged to form a matched external comparator group for Huntington’s disease using imaging and clinical endpoints.
Therapeutic Indication: Huntington's Disease (HD)

>View Study

Validation of IXIQ.Ai+gBSI : an automated framework for caudate atrophy measurement in Huntington’s disease

Date: May 4th 2023
Synopsis: Validation on 581 MRI scans from TRACK-HD and TRACK-ON HD demonstrated IXIQ.Ai + gBSI’s comparable sensitivity to manual methods in detecting disease progression over time.
Therapeutic Indication: Huntington's Disease (HD)

>View Study